Morpholino oligomer -: Mediated Exon skipping averts the onset of dystrophic pathology in the mdx mouse

被引:119
|
作者
Fletcher, Sue
Honeyman, Kaite
Fall, Abbie M.
Harding, Penny L.
Johnsen, Russell D.
Steinhaus, Joshua P.
Moulton, Hong M.
Iversen, Patrick L.
Wilton, Stephen D.
机构
[1] Univ Western Australia, Ctr Neuromuscular & Neurol Disorders, Perth, WA 6009, Australia
[2] Univ Western Australia, Royal Perth Hosp, Sch Med & Pharmacol, Cardiovasc Res Grp, Perth, WA 6009, Australia
[3] AVI BioPharma, Corvallis, OR USA
关键词
D O I
10.1038/sj.mt.6300245
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Duchenne and Becker muscular dystrophies are allelic disorders arising from mutations in the dystrophin gene. Duchenne muscular dystrophy is characterized by an absence of functional protein, whereas Becker muscular dystrophy, commonly caused by in-frame deletions, shows synthesis of partially functional protein. Anti-sense oligonucleotides can induce specific exon removal during processing of the dystrophin primary transcript, while maintaining or restoring the reading frame, and thereby overcome protein-truncating mutations. The mdx mouse has a non-sense mutation in exon 23 of the dystrophin gene that precludes functional dystrophin production, and this model has been used in the development of treatment strategies for dystrophinopathies. A phosphorodiamidate morpholino oligomer ( PMO) has previously been shown to exclude exon 23 from the dystrophin gene transcript and induce dystrophin expression in the mdx mouse, in vivo and in vitro. In this report, a cell-penetrating peptide ( CPP)- conjugated oligomer targeted to the mouse dystrophin exon 23 donor splice site was administered to mdx mice by intraperitoneal injection. We demonstrate dystrophin expression and near- normal muscle architecture in all muscles examined, except for cardiac muscle. The CPP greatly enhanced uptake of the PMO, resulting in widespread dystrophin expression.
引用
收藏
页码:1587 / 1592
页数:6
相关论文
共 50 条
  • [31] Impact of the Inhibition of Organic Anion Transporter on Tricyclo-DNA-Mediated Exon Skipping in the mdx Mouse Model
    Bizot, Flavien
    Tensorer, Thomas
    Garcia, Luis
    Goyenvalle, Aurelie
    NUCLEIC ACID THERAPEUTICS, 2023, 33 (06) : 374 - 380
  • [32] Treatment of Adult mdx Mice with Phosphorodiamidate Morpholino Oligomer Restores Cardiac Mitochondrial Energetics and Prevents the Dystrophic Cardiomyopathy
    Viola, Helena M.
    Johnstone, Victoria P. A.
    Adams, Abbie M.
    Fletcher, Susan
    Hool, Livia C.
    BIOPHYSICAL JOURNAL, 2017, 112 (03) : 245A - 245A
  • [33] Bubble Liposomes and Ultrasound Exposure Improve Localized Morpholino Oligomer Delivery into the Skeletal Muscles of Dystrophic mdx Mice
    Negishi, Yoichi
    Ishii, Yuko
    Shiono, Hitomi
    Akiyama, Saki
    Sekine, Shoko
    Kojima, Takuo
    Mayama, Sayaka
    Kikuchi, Taiki
    Hamano, Nohuhito
    Endo-Takahashi, Yoko
    Suzuki, Ryo
    Maruyama, Kazuo
    Aramaki, Yukihiko
    MOLECULAR PHARMACEUTICS, 2014, 11 (03) : 1053 - 1061
  • [34] Polyethylenimine-modified Pluronics (PCMs) Improve Morpholino Oligomer Delivery in Cell Culture and Dystrophic mdx Mice
    Wang, Mingxing
    Wu, Bo
    Lu, Peijuan
    Cloer, Caryn
    Tucker, Jay D.
    Lu, Qilong
    MOLECULAR THERAPY, 2013, 21 (01) : 210 - 216
  • [35] Demonstration of Systemic Exon 45-55 Multiple Skipping in Dystrophic mdx52 Mice
    Aoki, Yoshitsugu
    Nagata, Tetsuya
    Nakamura, Akinori
    Saito, Takashi
    Tanihata, Jun
    Duguez, Stephanie
    Nagaraju, Kanneboyina
    Hoffman, Eric
    Partridge, Terence
    Yokota, Toshifumi
    Takeda, Shin'ichi
    MOLECULAR THERAPY, 2012, 20 : S14 - S14
  • [36] Exon skipping and dystrophin restoration in Duchenne muscular dystrophy patients after systemic phosphorodiamidate morpholino oligomer treatment
    Cirak, S.
    Arechavala-Gomeza, V.
    Guglieri, M.
    Feng, L.
    Torelli, S.
    Anthony, K.
    Garralda, M. E.
    Wells, D.
    Dickson, G.
    Wood, M. J. A.
    Wilton, S. D.
    Straub, V.
    Shrewsbury, S. B.
    Sewry, C.
    Morgan, J. E.
    Bushby, K.
    Muntoni, F.
    NEUROMUSCULAR DISORDERS, 2011, 21 : S7 - S8
  • [37] Oligonucleotide Enhancing Compound Increases Tricyclo-DNA Mediated Exon-Skipping Efficacy in the Mdx Mouse Model
    Bizot, Flavien
    Fayssoil, Abdallah
    Gastaldi, Cecile
    Irawan, Tabitha
    Phongsavanh, Xaysongkhame
    Mansart, Arnaud
    Tensorer, Thomas
    Brisebard, Elise
    Garcia, Luis
    Juliano, Rudolph L.
    Goyenvalle, Aurelie
    CELLS, 2023, 12 (05)
  • [38] One-year Treatment of Morpholino Antisense Oligomer Improves Skeletal and Cardiac Muscle Functions in Dystrophic mdx Mice
    Wu, Bo
    Xiao, Bin
    Cloer, Caryn
    Shaban, Mona
    Sali, Arpana
    Lu, Peijuan
    Li, Juan
    Nagaraju, Kanneboyina
    Xiao, Xiao
    Lu, Qi Long
    MOLECULAR THERAPY, 2011, 19 (03) : 576 - 583
  • [39] Clinically Applicable Dosing Regimens of Phosphorodiamidate Morpholino Oligomer Profoundly Improve Behaviour, Activity, and Dystrophic phenotype in mdx mice
    Malerba, A.
    Sharp, P.
    Graham, I. R.
    Arechavala-Gomeza, V
    Foster, K.
    Morgan, J. E.
    Muntoni, F.
    Wells, D.
    Dickson, G.
    HUMAN GENE THERAPY, 2010, 21 (04) : 508 - 508
  • [40] Humoral and cell mediated immune response to new dystrophin after morpholino-induced exon skipping therapy in dystrophin-deficient mdx mice
    Nagaraju, K.
    Vila, M.
    Novak, J.
    Boehler, J.
    Hogarth, M.
    Zhang, A.
    Kinder, T.
    Mazala, D.
    Klimek, M. Benny
    Fiorillo, A.
    van den Anker, J.
    Hathout, Y.
    Hoffman, E.
    Partridge, T.
    NEUROMUSCULAR DISORDERS, 2018, 28 : S90 - S90